S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
NASDAQ:DFFN

Diffusion Pharmaceuticals (DFFN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$4.17
$5.19
50-Day Range
$4.38
$6.60
52-Week Range
$2.76
$7.40
Volume
351,000 shs
Average Volume
10,937 shs
Market Capitalization
$8.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

DFFN stock logo

About Diffusion Pharmaceuticals Stock (NASDAQ:DFFN)

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.


DFFN Stock News Headlines

Diffusion Pharmaceuticals Inc.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc. (DFFN)
DFFN: Phase 2 GBM Trial to Initiate 2H22…
See More Headlines
Receive DFFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DFFN
Employees
13
Year Founded
N/A

Profitability

Net Income
$-15,590,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.97 per share

Miscellaneous

Free Float
2,003,000
Market Cap
$8.98 million
Optionable
Not Optionable
Beta
1.78
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Robert J. Cobuzzi Jr. (Age 58)
    Ph.D., Pres & CEO
    Comp: $691.79k
  • Mr. William Robert Elder J.D. (Age 40)
    Gen. Counsel & Corp. Sec.
    Comp: $413.92k
  • Dr. David Randolph Jones M.D. (Age 60)
    Sr. Medical Advisor
  • Mr. Harry Cook
    VP of Clinical Operations
  • Mr. Douglas Gravatt
    Sr. Consultant for Manufacturing
  • Mr. Brian D. Bollwage
    Sr. Consultant - Regulatory Affairs














DFFN Stock Analysis - Frequently Asked Questions

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($9.00) EPS for the quarter, missing the consensus estimate of ($3.00) by $6.00.

When did Diffusion Pharmaceuticals' stock split?

Shares of Diffusion Pharmaceuticals reverse split on the morning of Thursday, August 17th 2023. The 1-1.5 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 67 shares after the split.

What other stocks do shareholders of Diffusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF).

This page (NASDAQ:DFFN) was last updated on 3/3/2024 by MarketBeat.com Staff